Belize vs Oman: HIV/AIDS deaths averted by antiretroviral therapy
Belize
87.27 deaths
in 2024
Oman
107.42 deaths
in 2024
Belize rank
127th
Oman rank
124th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Belize
- Oman
How they compare
Oman currently reports 107.42 deaths against 87.27 deaths in Belize, a difference of 20.15 deaths.
That makes Oman's figure about 1.2 times Belize's.
The two have swapped places 2 times across 35 shared years of data; in 1990 it was Oman ahead.
Belize ranks 127th and Oman ranks 124th of 157 countries.
Across the 4 decades both report, Belize averaged higher in 2 and Oman in 1.
Head to head by decade
| Decade | Belize | Oman | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 40.13 deaths | 32.99 deaths | 7.14 deaths | Belize |
| 2010s | 94.11 deaths | 53.22 deaths | 40.89 deaths | Belize |
| 2020s | 74.23 deaths | 86.92 deaths | 12.68 deaths | Oman |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Belize or Oman?
- Oman, at 107.42 deaths against 87.27 deaths in Belize as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Belize and Oman?
- 20.15 deaths, with Oman ahead.
- How many years of comparable data are there for Belize and Oman?
- 35 years are reported by both, from 1990 to 2024.
- How do Belize and Oman rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Belize ranks 127th and Oman ranks 124th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.